BRAF and metastatic melanoma: Moreover, selective B-Raf (V600E) inhibitors (Vemurafenib 2 and Dabrafenib 3, Fig. 1) showed significant clinical response in metastatic melanoma with oncogenic B-Raf mutation (V600E) (Ali et al. 2022).